LPL Financial LLC decreased its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 9.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 793,122 shares of the biopharmaceutical company’s stock after selling 85,011 shares during the period. LPL Financial LLC owned 0.06% of Gilead Sciences worth $75,796,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 85,547,536 shares of the biopharmaceutical company’s stock valued at $8,656,555,000 after buying an additional 596,921 shares in the last quarter. Temasek Holdings Private Ltd increased its position in Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the period. Norges Bank purchased a new position in Gilead Sciences during the fourth quarter worth approximately $1,308,213,000. Geode Capital Management LLC increased its position in Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock worth $1,137,969,000 after buying an additional 161,505 shares during the period. Finally, Morgan Stanley increased its position in Gilead Sciences by 18.0% in the fourth quarter. Morgan Stanley now owns 10,614,126 shares of the biopharmaceutical company’s stock worth $1,074,043,000 after buying an additional 1,616,773 shares during the period.
Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.67% during trading on Thursday, hitting $81.24. 12,994,030 shares of the stock traded hands. The company has a market capitalization of $108.13 billion and a P/E ratio of 7.13. The company’s 50 day moving average is $84.38 and its 200 day moving average is $88.64. Gilead Sciences Inc. has a one year low of $77.92 and a one year high of $120.37.
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.31%.
A number of equities analysts recently commented on the company. Vetr downgraded Gilead Sciences from a “buy” rating to a “hold” rating and set a $105.42 price target for the company. in a research note on Thursday, April 21st. Credit Suisse Group AG reiterated an “outperform” rating and issued a $120.00 price target (up from $116.00) on shares of Gilead Sciences in a research note on Thursday, April 28th. Cowen and Company reiterated a “buy” rating on shares of Gilead Sciences in a research note on Sunday, April 17th. Robert W. Baird reiterated an “outperform” rating and issued a $135.00 price target on shares of Gilead Sciences in a research note on Tuesday, April 12th. Finally, Citigroup Inc. decreased their price target on Gilead Sciences from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Friday, April 29th. Ten equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $109.95.
In related news, EVP Paul Rutherford Carter sold 2,000 shares of the stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $83.12, for a total value of $166,240.00. Following the transaction, the executive vice president now directly owns 63,122 shares in the company, valued at $5,246,700.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John F. Milligan sold 112,000 shares of the stock in a transaction that occurred on Monday, May 2nd. The shares were sold at an average price of $87.71, for a total transaction of $9,823,520.00. Following the completion of the transaction, the chief executive officer now owns 1,170,963 shares in the company, valued at $102,705,164.73. The disclosure for this sale can be found here.
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
